Streetbeat News

GRTX

Galera Therapeutics Inc

Employees

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

galera therapeutics, inc. is a pharmaceuticals company located in 101 lindenwood dr, malvern, pennsylvania, united states.

Open

0.03

Mkt cap

1.6M

Volume

107K

High

0.03

P/E Ratio

-0.06

52-wk high

0.29

Low

0.03

Div yield

N/A

52-wk low

0.02

Shares of Science Applications International Corporation (NASDAQ:SAIC) fell 11% following a 9% year-over-year revenue decline in Q1 2025, despite slightly beating revenue estimates and meeting EPS expectations. Other notable stock movements include Microbot Medical Inc. (NASDAQ:MBOT) jumping 92.5% after FDA approval for a clinical trial, and Bio-Path Holdings, Inc. (NASDAQ:BPTH) rising 75% following positive interim results from a Phase 2 study.

Portfolio Pulse from Avi Kapoor

June 03, 2024 | 5:56 pm

The article highlights significant intraday movements in health care stocks on Monday. Structure Therapeutics (GPCR) saw a 71% increase, while Concord Medical Services (CCM) rose by 55.96%. On the downside, CNS Pharma (CNSP) and Galera Therapeutics (GRTX) experienced declines of 32.2% and 31.67%, respectively.

Portfolio Pulse from Benzinga Insights

June 03, 2024 | 4:31 pm

Galera Therapeutics Inc (NASDAQ:GRTX) shares plummeted by 34.8% to $0.14 after receiving a delisting notice from Nasdaq due to non-compliance with listing standards. Trading will be suspended on June 4, 2024, and the company plans to move to OTC Markets Group.

Portfolio Pulse from Henry Khederian

June 03, 2024 | 3:17 pm

Galera Therapeutics shares are trading lower after the company announced it will be delisted by Nasdaq.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:16 pm

The article highlights the pre-market movements of 12 health care stocks on Monday. Notable gainers include Bio-Path Holdings (BPTH) up 70.4%, Molecular Partners (MOLN) up 21.72%, and Structure Therapeutics (GPCR) up 19.23%. Significant losers include Galera Therapeutics (GRTX) down 36.5%, Portage Biotech (PRTG) down 20.99%, and iSpecimen (ISPC) down 17.4%.

Portfolio Pulse from Benzinga Insights

June 03, 2024 | 12:07 pm

Galera Therapeutics will be delisted by Nasdaq, with trading suspended on June 4. Shares are expected to trade on the OTC market under the symbol 'GRTX'.

Portfolio Pulse from Charles Gross

June 03, 2024 | 11:10 am

The article highlights the performance of various health care stocks during Wednesday's after-market session. Notable gainers include OneMedNet (ONMD), Kintara Therapeutics (KTRA), and Galera Therapeutics (GRTX), while significant losers include Onconetix (ONCO), Agilent Technologies (A), and Immunovant (IMVT).

Portfolio Pulse from Benzinga Insights

May 29, 2024 | 8:31 pm

Galera Therapeutics reported having cash and cash equivalents of $13.5 million, which is expected to provide the company with a cash runway into the third quarter of 2025.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 11:16 am

Galera Therapeutics reported a Q1 2024 GAAP EPS of $(0.08), surpassing the $(0.35) estimate. This performance indicates a significant positive deviation from expected financial results.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 11:15 am

In Friday's after-market session, several healthcare stocks experienced significant movements. NeuBase Therapeutics, Aptevo Therapeutics, Galera Therapeutics, Alzamend Neuro, Asensus Surgical, and cbdMD were among the gainers, with increases ranging from 5.24% to 11.1%. Conversely, Acutus Medical, HeartBeam, Mustang Bio, Palisade Bio, Trevena, and Monopar Therapeutics saw declines between 5.0% and 16.4%.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 8:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.